Vraylar (Cariprazine) Half-Life
Vraylar has a complex half-life profile: cariprazine itself has a half-life of 2-4 days, but its major active metabolite didesmethylcariprazine (DDCAR) has a much longer half-life of approximately 1-3 weeks (or more specifically, 2-3 weeks based on terminal elimination data). 1
Key Pharmacokinetic Details
Parent Drug and Metabolites
Cariprazine is metabolized into two major active metabolites that are pharmacologically equipotent to the parent drug:
- Cariprazine: Half-life of 2-4 days 1
- Desmethylcariprazine (DCAR): Half-life of approximately 1-2 days 1
- Didesmethylcariprazine (DDCAR): Half-life of approximately 1-3 weeks, with terminal half-life data showing 314-446 hours (approximately 13-19 days) 2
Clinical Implications of the Long Half-Life
The prolonged half-life of DDCAR creates critical clinical considerations:
- Time to steady state: Cariprazine and DCAR reach steady state in 1-2 weeks, but DDCAR takes 4-8 weeks to approach steady state 1
- Effective half-life of total active moieties: Approximately 1 week 2
- Time to reach steady state varies significantly between patients, with some not achieving steady state even after 12 weeks of treatment 1
Post-Discontinuation Kinetics
After stopping Vraylar 1:
- Cariprazine and DCAR plasma concentrations decline by approximately 90% within 1 week
- DDCAR decreases by only about 50% at 1 week post-discontinuation
- Total active moieties decline by approximately 90% within 4 weeks
- Following a single 1 mg dose, DDCAR remained detectable 8 weeks post-dose
Critical Clinical Warnings
Because of these long half-lives, prescribers must monitor patients for adverse reactions and treatment response for several weeks after starting Vraylar and after each dosage change. 1 Changes in dose will not be fully reflected in plasma for several weeks due to the prolonged accumulation of DDCAR.
The World Brain Death Project consensus recommends delaying clinical examination until at least five elimination half-lives of the longest-acting drug administered 3. For Vraylar, this would translate to approximately 10-15 weeks for complete elimination of DDCAR, though this context applies to brain death determination rather than routine clinical management.